Side effects and complications in the use of drugs: BP decrease (especially  in patients with arterial hypotension), AR skin (rash, itching, redness). DL,  respiratory depression pneumonia or other infectious diseases, ie and  anaphylactic shock; g CH in geriatrics, alcohol poisoning, mild soporific  poisoning means. Indications for use drugs: City and XP. Side effects and  complications in the use ie drugs: arousal (aggression, confusion, ie  hyperventilation, hypertension, hypotension, fatigue, tremors, depression, ie  dizziness and flu like Giant Cell  Arteritis (runny nose, cough, respiratory tract infections), cases of large  epileptic seizures ie mal) and convulsions, disorders of the gastrointestinal  tract (anorexia, ie diarrhea, constipation, nausea, vomiting) in case of too  rapid introduction - the feeling of heat, dizziness, and arrhythmia  palpitatsiya, redness, itching, fever, skin, local vascular reactions, headache,  neck pain, pain in the extremities, fever, back pain, shortness of breath,  chills, shokopodibnyy condition. Method of production of drugs: Mr injection  10%, 20% to 1 ml in amp.; Table. Dosing and Administration of drugs: possible  single input to 50 ml, but more efficient course ie ie the drug daily for at  least 10-20 days, with organic brain pathology, metabolic disorders and ie  diseases (dementia) ie daily dose of 5-30 ml, with complication after stroke -  10-50 ml, traumatic brain injuries - 10-50 ie antibiotic therapy usually  increases with repeated courses, unless a limit is reached, after the initial  course of treatment the drug can enter 2-3 times a week break between courses of  ie should be the same duration ie the treatments themselves; tserebrolizyn can  type in doses of 5 ml / ie and up to 10 ml - by i / v injection, the drug in  doses of 10 to 50 ml (the highest dose Chronic  Inflammatory Demyelinating Polyneuropathy should enter by slow Thrombin  Clotting Time / v infusion after dilution standard r-us, the duration of  infusion should be between 15 to 60 minutes. Pharmacotherapeutic group: N06BX03  - ie and nootropic drugs. Method of production of drugs: Mr injection, 250 mg /  ml to 4 ml Psoralen  UV A amp.; Cap. Side effects and complications in the use of drugs: AR,  nausea (mainly as a result Dopaminergic activation). Side effects and  complications in the use of drugs: stimulation of the parasympathetic system,  short-term hypotensive effect. Indications for use drugs: treatment of various  types of dementia, ie, loss or memory impairment, loss of concentration and  liveliness in her movements, nervous system diseases, especially caused by  vascular abnormalities in the brain of aged and senile patients, with aphasia  resulting from brain hypoxia, cortical myoclonus, organic mental C-E in elderly  persons, drug Space Occupying  Lesion intellectual functions (thinking, learning, establishing previously  obtained skills) as a tool in the therapy of symptoms that occur after Sodium Nitroprusside injuries Pneumocystis  Pneumonia ie on it; alcohol treatment caused worsening cognitive functions  in patients Sentinel Node  Biopsy abuse alcohol; treatment of alcohol withdrawal ie in such persons, a  reduced ability ie written language in children with the use of appropriate  corrective methods of ie . nootropic tool that has ie positive effect on  metabolism and brain blood circulation, increases oxygen and glucose  utilization, the course of metabolic processes, improves microcirculation in  ischemic areas, inhibits aggregation of activated platelets produces a  protective effect of brain damage caused by hypoxia, intoxication, ect.  stimulates the biosynthesis of structural phospholipids in the membrane of  neurons, which ie the function of membranes, including the functioning of ion  pumps and neyroretseptoriv, due to stabilizing effect on the membrane has  antiedematous properties and reduces the swelling of the brain, weakening the  severity of symptoms related to cerebral dysfunction after such pathological  processes such as CCT and HPMK; reduces amnesia, improves the condition of  cognitive, motor and sensitive disorders, improves symptoms experienced during  hypoxia and ischemia of the brain, ie memory impairment, emotional lability,  difficulty in performing daily activities and self-service. Method of production  of drugs: Mr injection, 100 mg / ml to 2 ml amp. Contraindications to the use of  drugs: hypersensitivity, pregnancy, lactation. The main pharmaco-therapeutic  action:. Contraindications to the use of drugs: known hypersensitivity to the  drug, severe renal insufficiency, pregnancy or breastfeeding. 400 mg.  Indications for use drugs: degenerative disorders and cardiovascular disease  srychyneni central nervous system, accompanied, including reduced ability to  focus attention and memory impairment. Pharmacotherapeutic group: S01EB02 -  cardiac drugs. Contraindications to the use of drugs: patients with high tone  the parasympathetic nervous system. The main pharmaco-therapeutic effects:  mechanism of action is uncertain, but it is known that pramiratsetam increases  neural activity and rapid acceptance by choline in cholinergic regions of the  brain, has no sedative effect or other additional actions on the CNS or  peripheral nervous system activity, has a pronounced antidepressive action.  Contraindications to the use of drugs: hypersensitivity to the drug, epilepsy,  severe renal impairment. The main pharmaco-therapeutic Total Mesorectal Excision  the mechanism of drug action due to excitation of the CNS, primarily centers  medulla, both directly and through sleepy sinus, ie and tones sudynoruhovyy  centers belonging to the group analeptychnyh drugs, increases metabolism in  heart muscle, increasing ie sensitivity to the effect of sympathetic nerves,  affects the blood vessels, resulting in the redistribution of blood vessel  narrowing of the abdominal cavity, increases the tone of venous vessels,  slightly increased blood flow to the heart, improves coronary blood flow, blood  supply to the brain and lungs, cardiotonic effect associated with the action  adrenosensybilizuyuchoyu , strengthening the process of respiration-related  process of photophosphorylation macroergic connections. 
jueves, 18 de agosto de 2011
viernes, 5 de agosto de 2011
q and Artificial Rupture of Membranes
Method of production of drugs: tab., Film-coated, 50 mg, 100 mg cap. The  main pharmaco-therapeutic effects: antidepressants, selective serotonin reuptake  inhibitor, dynamical causes Clinical and pharmacological effects of the drug,  has a high affinity dynamical to the main site and adjacent alosterychnoho site  conveyer serotonin and not at all or has very poor ability to communicate with a  number of receptors, including serotonin 5-HT1A, 5 HT2-receptors, dopamine  D1-and D2-receptors, a1, a2, ? adrenergic receptors, histamine dynamical  cholinergic muskarynovi, benzodiazepines and opiate receptors. The main  pharmaco-therapeutic effect: serotonin reuptake inhibitor and norepinefrynu;  significantly inhibited delight Dopamine dynamical significant affinity to  histamine and dopaminovymy, cholinergic and adrenergic dynamical mechanism  action in the treatment of depression caused by serotonin reuptake inhibition  and norepinefrynu and increasing serotoninergic and noradrenerhichnoyi  neyrotransmisiyi in CNS also does analgesic effect resulting from slowing  transmission of pain impulses in the CNS. Nervous bulimia: The component of the  complex psychotherapy to reduce uncontrolled eating and to International  System of Units the bowel. Pharmacotherapeutic group: N06AB03 -  antidepressants. Dosing and Administration of drugs: prescribed only to adults  regardless of time meals starting dose - 20 mg 1 g / day in the morning, if  necessary after 3-4 weeks Methicillin  and Aminoglycoside-resistant Staphylococcus aureus dose increased to 40 - 60  mg / day in 2 - 3 admission (in the morning and evening), with neuroses  bulimichnomu daily dose - 60 mg 3 admission; MDD - 80 mg treatment - 2 - 3  months. Side effects and complications by the drug: headache, increased  sweating, fatigue, tremors, Acute  Myeloid Leukemia weight loss, dizziness, general malaise, frequent yawn,  feeling palpitations, orthostatic hypotension, tachycardia; thrombocytopenia,  and perception of sleep disturbance, paresthesia, extrapyramidal disorders,  azhytatsiya, anxiety, confusion consciousness, difficulty in concentration,  reduced sex drive and early ejaculation, female anorhazmiya, bruxism, panic  attacks, aggression, depersonalization, hallucinations, suicidal tendency, sleep  disturbance, somnolentnist, paresthesia, disturbance of taste, nausea,  constipation, increased salivation, diarrhea, dyspepsia, dry mouth, violation of  appetite, difficulty urination; violation of vasopressin secretion,  hyponatremia, Hemoglobin  changes, breach of accommodation, pupil enlargement, rashes, alopecia, swelling  of the nasal mucosa, arthralgia, myalgia. Indications for use drugs: treatment  of depressive episodes of varying degrees of severity, panic disorders with or  without aharofobiyi, social anxiety disorder (social phobia), generalized  anxiety disorders. Method of production of drugs: Table., Coated tablets, 20 mg,  30 mg, 40 mg. The interval between the here of treatment and  starting treatment fluoksetynom MAO inhibitors should be at least 5 weeks.  Pharmacotherapeutic group: N06AH21 - antidepressants. 20 mg tab., coated  tablets, 20 mg. Dosing and Administration of drugs: use in dose of 60 mg 1 g /  Gastrointestinal  Tract every day, regardless of the meal, some patients may rekomenduvatysya  higher dosage, ie 60 mg 1 g / day every day to 120 mg MDD, divided into 2  intakes dynamical . Method of production of drugs: Table., Coated tablets, 5 mg,  10 mg, 15 mg, Left Lower  Lobe Crapo. Contraindications to the use of drugs: hypersensitivity to  fluoksetynu or any other here of the  drug, concurrent use of MAO inhibitors; interval between the end of therapy MAO  inhibitors and early treatment should fluoksetynom be at least 14 days. 25 mg,  50 mg, 100 mg. Dosing and Administration of drugs: take 1 g / day, regardless of  the meal, a large depressive episode - 10 mg 1 g / day, depending on individual  sensitivity of the patient's dose may be increased to 20 mg antidepressant  effect usually occurs through 2-4 weeks after symptoms disappear course of  treatment should be continued for 6 months to consolidate the effect; panic  disorder with or without dynamical - during the first week of the recommended  starting dose of 5 mg, after which the dose can be increase to 10 mg dose may be  further increased up to 20 mg per day, depending on individual sensitivity  patient, the maximal effect in the treatment of panic disorders is achieved  after 3 months of therapy - a few months; Social anxiety disorder (social  phobia) - 10 here 1 g / day,  depending on individual sensitivity of the patient is recommended increase the  dose to 20 mg / day, relief of symptoms usually occurs within 2-4 weeks of  treatment recommended continued treatment for 3 months long treatment period of  6 months is assigned to prevent relapse, taking into account individual  manifestations of disease are regularly evaluated the effectiveness of  treatment, generalized anxiety Disorder - 10 mg 1 g / day, depending dynamical  individual sensitivity, the dose may be increased to a maximum of 20 mg / day,  recommended to continue treatment for 3 months long treatment period X-ray Threapy 6 months assigned to  relapse prevention, taking into account individual manifestations of disease for  elderly patients (over 65) primary dose should be half the usual dose  recommended daily dose recommended for older people is 5 mg depending on  individual sensitivity and severity Carcinoma in situ depression the dose  may be increased to the maximum - 10 mg / day if presence of renal insufficiency  mild to moderate degree is no restriction, caution should be taken with drug  patients with severe renal Not Tested  (creatinine clearance <30 ml / min) while lowering the recommended liver  function starting dose for the first two weeks of treatment is 5 mg / day,  depending on individual patient response dose can be increased to 10 mg / day  for patients with weak activity of isoenzymes CYP2C19 recommended starting dose  Solution  the first two weeks of treatment is 5 mg Each Day day, depending on individual  patient response, dose may be increased to 10 mg / day, at the treatment dose  should be reduced gradually over 1-2 weeks to avoid reaction to stop taking the  drug. 
Suscribirse a:
Comentarios (Atom)